Nova Mentis Life Science Corp (CSE: NOVA) (FSE: HN3Q) (OTCPK: NMLSF)

The Nova Mission

We’re a Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Our mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome.

Nova is the first company to achieve psilocybin orphan drug
designation in both the U.S. and European Union for the treatment of
fragile X syndrome, the leading genetic cause of symptoms
related to autism spectrum disorder.

This provides us with financial benefits, market exclusivity,
research assistance and access to grants.

Autism Spectrum Disorder and Fragile X Syndrome Observational Study

Learn More

Latest News

Sept 29, 2022

Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application

Vancouver, British Columbia – September 29, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that the company has produced 1.5 mg psilocybin microdose capsules. These capsules ...

Sept 15, 2022

Nova Mentis Completes Production of Psilocybin Microdose Capsules
Company Plans to Submit Clinical Trial Application in Canada

Vancouver, British Columbia – September 15, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has completed production